High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: A new regimen for the treatment of advanced ovarian cancer

Gynecologic Oncology

Volumn 82, Issue 3, 2001, Pages 420-426

  Donato, Michele L ^a   Gershenson, David M ^a   Wharton, James T ^a   Ippoliti, Cindy M ^a   Aleman, Ana S ^a   Bodurka Bevers, Diane ^a   Bevers, Michael W ^a   Burke, Thomas W ^a   Levenback, Charles F ^a   Wolf, Judith K ^a   Freedman, Ralph S ^a   Bast Jr , Robert C ^a   Gajewski, James L ^a   Champlin, Richard E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; MELPHALAN; TOPOTECAN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; DIARRHEA; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; OVARY CANCER; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 17944374801     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6326     Document Type: Article

References (43)

1. Trends in United States ovarian cancer mortality, 1979-1995
2. Trends and differentials in ovarian cancer: Incidence, mortality and survival experience
3. Ovarian cancer: Age contrasts in incidence, histology, disease stage at diagnosis, and mortality
4. Long-term results and prognostic factors in patients with epithelial ovarian cancer
5. The importance of dose intensity in the outcome of chemotherapy
6. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer
7. Effective high-dose chemotherapy with autologous bone marrow infusion in resistant ovarian cancer
8. High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer
9. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support
10. High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer
11. Peripheral blood and bone marrow hematopoietic stem cells: Are they the same?
12. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow
13. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care
14. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: A multivariate analysis of survival for 100 consecutively treated patients
15. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: Long-term results
16. High-dose intravenous melphalan: A review
17. Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients
18. Paclitaxel-containing high-dose chemotherapy: The University of Colorado experience
19. Acute encephalopathy: A new toxicity associated with high-dose paclitaxel
20. Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients
21. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma
22. Topotecan: A novel topoisomerase I inhibitor: Pharmacology and clinical experience
23. Clinical guidelines for managing topotecan-related hematologic toxicity
24. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines
25. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer
26. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer
27. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125
28. Regimen-related toxicity in patients undergoing bone marrow transplantation
29. The chemotherapeutic drug melphalan induces breakage of chromosomes regions rearranged in secondary leukemia
30. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation
31. Risk of acute myelogenous leukaemia and myelodys-plasia following cancer treatment
32. Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer
33. Phase I study of repetitive high-dose topotecan, carboplatin and paclitaxel with peripheral blood progenitor cell support for patients with previously untreated ovarian cancer
34. Analysis of failures after negative second-look in patients with advanced ovarian cancer: An Italian multicenter study
35. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings
36. Second-look laparotomy in advanced ovarian cancer: A critical assessment of morbidity and impact on survival
37. Surgical second look in ovarian cancer: A randomized study in patients with laparoscopic complete remission: A Northeastern Oncology Cooperative Group-Ovarian Cancer Cooperative Group Study
38. Second-look laparotomy in ovarian cancer
39. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
40. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
41. Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy
42. Clear cell carcinoma of the ovary: Poor prognosis compared to serous carcinoma
43. Impact of stem cell dose on hematopoietic recovery in autologous blood stem cell recipients